Azitra is pioneering the use of engineered live biotherapeutics to treat genetic and inflammatory skin conditions. Its lead program, AZT-01, is in late-stage development for DEB, with interim data showing compelling wound healing outcomes. The company is also preparing an IND for AZT-02, targeting Netherton syndrome with a first-in-class topical microbiome approach.